These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 29372566)
21. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease. Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924 [TBL] [Abstract][Full Text] [Related]
22. Signal detection theory approach to gastroesophageal reflux disease: a new method for symptom analysis of impedance-pH data. Giral A; Kurt R; Yeğin EG; Yeğin K Dis Esophagus; 2014 Apr; 27(3):206-13. PubMed ID: 23795569 [TBL] [Abstract][Full Text] [Related]
24. AGA Clinical Practice Update on Functional Heartburn: Expert Review. Fass R; Zerbib F; Gyawali CP Gastroenterology; 2020 Jun; 158(8):2286-2293. PubMed ID: 32017911 [TBL] [Abstract][Full Text] [Related]
25. 24-hour pH-impedance monitoring on therapy to select patients with refractory reflux symptoms for antireflux surgery. A single center retrospective study. Desjardin M; Luc G; Collet D; Zerbib F Neurogastroenterol Motil; 2016 Jan; 28(1):146-52. PubMed ID: 26526815 [TBL] [Abstract][Full Text] [Related]
31. How to differentiate non-erosive reflux disease from functional heartburn. Ke MY J Dig Dis; 2012 Dec; 13(12):605-8. PubMed ID: 23134478 [TBL] [Abstract][Full Text] [Related]
33. Lack of improvement of impaired chemical clearance characterizes PPI-refractory reflux-related heartburn. Frazzoni M; Frazzoni L; Tolone S; De Bortoli N; Savarino V; Savarino E Am J Gastroenterol; 2018 May; 113(5):670-676. PubMed ID: 29681623 [TBL] [Abstract][Full Text] [Related]
34. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients. Bytzer P; van Zanten SV; Mattsson H; Wernersson B Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764 [TBL] [Abstract][Full Text] [Related]
35. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS? Azzam RS Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291 [TBL] [Abstract][Full Text] [Related]
36. Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease. Slaughter JC; Goutte M; Rymer JA; Oranu AC; Schneider JA; Garrett CG; Hagaman D; Vaezi MF Clin Gastroenterol Hepatol; 2011 Oct; 9(10):868-74. PubMed ID: 21782769 [TBL] [Abstract][Full Text] [Related]
37. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease. Pace F; Pace M Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):423-7. PubMed ID: 20678016 [TBL] [Abstract][Full Text] [Related]
38. [The Additional Role of Symptom-Reflux Association Analysis of Diagnosis of Gastroesophageal Reflux Disease Using Bravo Capsule pH Test]. Jung K; Park MI; Park SJ; Moon W; Kim SE; Kim JH Korean J Gastroenterol; 2017 Oct; 70(4):169-175. PubMed ID: 29060954 [TBL] [Abstract][Full Text] [Related]
39. Overweight is a risk factor for both erosive and non-erosive reflux disease. Savarino E; Zentilin P; Marabotto E; Bonfanti D; Inferrera S; Assandri L; Sammito G; Gemignani L; Furnari M; Dulbecco P; Savarino V Dig Liver Dis; 2011 Dec; 43(12):940-5. PubMed ID: 21944835 [TBL] [Abstract][Full Text] [Related]